Biogen Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −2.07%.
Did BIIB Beat Earnings? Q4 2025 Results
Biogen delivered a mixed but fundamentally encouraging fourth quarter, posting non-GAAP diluted EPS of $1.99 against a $1.61 consensus estimate, a 23.60% beat driven largely by disciplined cost management under the company's Fit for Growth initiative, even as revenue of $2.28 billion fell fractionally short of the $2.29 billion estimate and declined 7.10% year-over-year. The headline profit figure masked considerable complexity beneath the surface: GAAP results reflected a net loss of $48.90 million, weighed down by $131.00 million in litigation charges and $222.00 million in acquired IPR&D and milestone expenses, while the legacy multiple sclerosis franchise continued its structural retreat with MS product revenue of $917.00 million declining 14% in the quarter. The more forward-looking story belongs to growth products, where LEQEMBI's global in-market sales climbed 54% year-over-year to roughly $134.00 million and SKYCLARYS and ZURZUVAE added meaningful momentum. Looking ahead, Biogen guided for full-year 2026 non-GAAP EPS of $15.25 to $16.25, though it also projected a mid-single digit revenue decline as MS erosion continues to pressure the top line, a dynamic familiar to <a href="https://247wallst.com/investing/2026/02/05/bristol-myers-just-crushed-earnings-and-the-real-catalyst-hasnt-even-hit-yet/">large-cap biopharma peers navigating franchise transitions</a>.
- Growth products revenue up 6% YoY in Q4 and 19% for full year, offsetting MS franchise declines
- LEQEMBI global in-market sales of approximately $134 million in Q4, up 54% YoY
- SKYCLARYS grew global patients on therapy by approximately 30% in 2025
- ZURZUVAE showed strong continued demand growth with Q4 revenue of approximately $66 million
- Anti-CD20 therapeutic program revenue grew 12% YoY in Q4
- Favorable product mix drove lower Non-GAAP cost of sales as percentage of revenue
- Fit for Growth initiative delivered R&D expense savings
“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise. Our pipeline momentum continues with a strong start in 2026, with the FDA recently granting Priority Review for LEQEMBI IQLIK initiation and Breakthrough Therapy Designation for litifilimab in CLE. These milestones highlight both the innovative and differentiated value of our medicines and the strength of our late-stage pipeline. Going into 2026, we are looking forward to data from two Phase 3 studies in lupus for litifilimab, with 10 additional potentially registrational studies across our pipeline expected to read out sequentially over the next four years. This multi-year registrational data flow has the potential to drive meaningful innovation for patients and long-term value for shareholders.”
Biogen CEO, on the earnings call
Forward Guidance & Outlook
For full year 2026, Biogen expects Non-GAAP diluted EPS of $15.25 to $16.25. Total revenue is expected to decline by a mid-single digit percentage versus full year 2025, as further declines in multiple sclerosis product revenue (excluding VUMERITY) are expected to be partially offset by increases in revenue from growth products. Gross margin percentage and combined Non-GAAP R&D and SG&A expense are expected to be roughly consistent year-over-year. Non-GAAP effective tax rate is expected to be between approximately 17% and 18%. Guidance assumes foreign exchange rates as of January 30, 2026 remain in effect for the remainder of the year.
BIIB YoY Financials
BIIB Revenue by Segment
BIIB Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.